News Agency
The Times

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

  • Written by Media Outreach

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE - Media OutReach - 6 June 2022- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that PADCEV™ (enfortu...

Read more: PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer...

How to Choose a Local SEO Agency That Can Generate Real Enquiries, Not Just Rankings

A local SEO proposal may promise improved Google Maps visibility, extra keywords, and monthly reports. Those can be useful, but they do not automatically mean the business will receive more calls from suitable customers. Before committing to a contract, owners... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion